YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Collins on the FDA Approval of Illumina's MiSeqDx


November 20, 2013 | Yesterday the FDA granted premarket clearance to Illumina's MiSeqDx platform as well as several diagnostic kits to go with the platform. Francis Collins, in a Perspective comment at the New England Journal of Medicine, said that the FDA's authorization will open the door "for the development and use of innumerable new genome-based tests." In his statement on the NIH website, Collins called the approval, "a landmark move that will help to realize the promise of personalized medicine", but also a first step, stressing that there is still work needed to establish the clinical validity of new genomic findings before they are incorporated into medical decision-making.
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.